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ENGLISH SUMMARY 
Background:. Patient-reported outcomes (PROs) applied to clinical practice have 
proven successful in providing patient-centered care in terms of increased patient 
involvement, improved provider-patient communication and as support to shared 
decision making. Patients with hematological cancer report unmet supportive care 
needs throughout their experience with the disease. These unmet needs are 
associated with impaired health-related quality of life (HRQoL) expressed as 
impairment of physical, physiological and social functioning as well as increased 
symptom burden. Thus, these patients face a variety of challenges along the disease 
trajectory, which are not fully meet today, underpinning the importance of 
investigating if PROs have the potential to enhance patient-centered care and quality 
of care in patients with hematological cancer. 
 
Aim: The overall aim of this PhD thesis was to examine the potential of PROs among 
patients with hematological cancer along the disease trajectory and to determine if 
PROs could facilitate patient-centered care and contribute to increased quality of 
care in this population.  
 
Method: This PhD thesis incorporates a multi-method research design consisting of 
three studies. In Study I, the feasibility of a shared care follow-up initiative for 
patients with B-cell disease was tested. The shared care follow-up initiative was 
based on alternating in-hospital physician visits and nurse-led telephone 
consultations based on PRO data. The study involved a survey of the patients’ 
acceptability towards completing PROs as part of follow-up. Study II involved 
qualitative interviews exploring patients’ experiences with participating in the 
shared care follow-up initiative. Study III was a longitudinal observational HRQoL 
study investigating HRQoL patterns during one year in a cohort of patients with 
hematological cancer who had relapsed or progressive disease.  
 
Results: In Study I, the shared care follow-up proved feasible, yielding high patient 
adherence and receptivity to completing PRO measures expressed as; a) increased 
involvement in treatment (48/56 [86%]); b) easier recollection of symptoms (50/57 
[88%]), and  c) improved communication with the health professionals (51/57 [90%]). 
Study II described five themes that the participating patients experienced in the 
shared care follow-up initiative, finding positives in more aspects of everyday life and 
a shift in focus during the consultations from disease and treatment to psychological 
issues. Most patients were positive towards completing PROs as part of follow-up; 
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however, a few patients found the questions to be irrelevant and that it was difficult 
to get the message across. Study III demonstrated that patients with relapsing or 
progressive hematological disease reported moderate or severe symptoms or 
functional problems at baseline and that some patients experienced deterioration in 
HRQoL in the first year after a relapse diagnosis. Furthermore, a statistically 
significant correlation between impaired role functioning and estimated survival ≤2 
years was found (OR 0.14, CI: 0.02; 0.95, p=0.04). 
 
Conclusion: Overall, this multi-method PhD thesis demonstrates that PROs are 
valuable on the trajectory of hematological cancer in terms of increased patient 
involvement, identifying health problems, and improving patient–provider 
communication and as a supporting role in shared decision making. Although 
divergent patient experiences suggest that a one-size-fits-all approach is 
undesirable, PROs seem to provide health professionals with a valid tool in the 
pursuit of providing patient-centered care. 
 
Implications for clinical practice: PROs may have the potential to target and 
individualize survivorship care of patients with hematological cancer. Basing 
survivorship care on a multi-disciplinary approach may allow for a more holistic 
approach to a patient’s supportive care needs. To address deterioration in HRQoL 
during relapse treatment, implementation of PROs in hematological clinical practice 
may offer the opportunity to address symptoms earlier and support patients in 
maintaining usual activities.  
 
Future research: Development and implementation of PRO-based interventions 
should be preceded by qualitative research studies exploring patient needs and 
preferences for the intervention in question, ensuring a solid foundation for future 
PRO-based interventions. The results of this research indicated a large symptom 
burden as well as deterioration in HRQoL among patients with relapse or progressive 
disease. To address symptoms and supportive care needs during treatment for 
relapsed or progressive disease, further research should encompass symptom 
monitoring based on PROs during treatment of these patients to identify potential 





Baggrund: Anvendelsen af PRO data (patient-rapported outcomes) har vist siga at 
være værdifuld i forbindelse med patient-centreret pleje og behandling i klinisk 
praksis. PRO data har blandt andet vist fordele i forhold til øget patientinvolvering, 
forbedret kommunikation mellem patient og sundhedsprofessionelle og som støtte 
til fælles beslutningstagning. Hæmatologiske kræftpatienter rapporterer om 
uopfyldte behov i forbindelse med håndtering af sygdommen og følger til 
sygdommen i løbet af deres sygdomsforløb. Uopfyldte behov for støtte er associeret 
med nedsat helbredsrelateret livskvalitet i form af forringet fysisk, psykisk og social 
funktion og øget symptombyrde. Hæmatologiske kræftpatienter oplever således 
adskillige udfordringer i løbet af deres sygdomsforløb, som på nuværende tidspunkt 
ikke fuldt ud bliver mødt. På den baggrund er det vigtigt at undersøge, hvorvidt PRO 
data potentielt kan understøtte patient-centreret pleje og behandling. 
 
Formål: Det overordnede formål med dette Ph.d.-projekt var at undersøge PRO 
datas potentiale hos hæmatologiske kræftpatienter i løbet af deres sygdomsforløb 
og klarlægge, hvorvidt PRO data kunne facilitere patient-centreret pleje og 
behandling og bidrage til øget kvalitet af pleje og behandling hos denne 
patientgruppe. 
 
Metode: Dette Ph.d.-projekt er designet som et multi-metode forskningsprojekt, der 
indeholder 3 studier. I Studie I blev gennemførbarheden af et tværfagligt 
opfølgningsforløb for patienter med B-celle sygdom undersøgt. Det tværfaglige 
opfølgningsforløb var baseret på skiftevis opfølgning hos patientens ansvarlige læge 
og telefoniske sygeplejerskekonsultationer baseret på PRO data. Inkluderet i studiet 
var en undersøgelse af patienternes villighed til at udfylde spørgeskemaer, som en 
del af opfølgningsforløbet. Studie II var et kvalitativt interview studie, der havde til 
formål at undersøge patienternes oplevelser med at deltage i det tværfaglige 
opfølgningsforløb. Studie III var et longitudinelt observationelt studie, der 
undersøgte mønstre i udviklingen af helbredsrelateret livskvalitet hos 
hæmatologiske patienter med relaps eller progressiv sygdom i løbet af det første år 
efter relapsdiagnosen.  
 
Resultater: I Studie I blev det tværfaglige opfølgningsforløb fundet gennemførbart 
som resultat af høj patientdeltagelse og høj modtagelighed i forhold til at udfylde 
spørgeskemaer. Undersøgelsen af patienternes villighed til at udfylde 
spørgeskemaer viste, at 48/56 [86%] patienter oplevede øget involvering, 50/57 
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[88%] patienter huskede nemmere symptomer og 51/57 [90%] patienter oplevede 
forbedret kommunikationen med de sundhedsprofesionelle.  Studie II beskrev fem 
temaer over patienternes oplevelser med at deltage i det tværfaglige 
opfølgningsforløb og fandt, at det tværfaglige opfølgningsforløb havde positiv 
indflydelse på flere aspekter af hverdagslivet, ligesom de oplevede et skift i fokus i 
under konsultationerne fra sygdom og behandling til psykologiske spørgsmål. De 
fleste patienter var positive i forhold til at udfylde spørgeskemaer, men nogle 
patienter fandt spørgsmålene irrelevante og svært at få sit budskab igennem. Studie 
III viste, at hæmatologiske patienter med relaps eller progressiv sygdom 
rapporterede moderate eller alvorlige symptomer og/eller funktionelle problemer 
ved baseline og at nogle patienter oplevede forværring af helbredsrelateret 
livskvalitet 12 måneder efter relapsdiagnosen. Derudover, viste Studie III en statistisk 
signifikant association mellem nedsat rollefunktion og estimeret overlevelse ≤2 år 
(OR 0.14, CI: 0.02; 0.95, p=0.04). 
 
Konklusion: Samlet viser dette multi-metode Ph.d.-projekt, at PRO data er 
værdifulde i løbet af et hæmatologiske sygdoms- og behandlingsforløb i form af øget 
patientinvolvering, identifikation af sundhedsproblemer, forbedring af 
kommunikation mellem patient og sundhedsprofessionelle og som en 
understøttende rolle i fælles beslutningstagen. Selvom divergerende 
patientoplevelser antyder, at en enhedsløsning er uhensigtsmæssig, ser det ud til at 
PRO kan anvendes som et validt værktøj til  patient-centreret pleje og behandling. 
 
Implikationer for klinisk praksis: PRO data indeholder et muligt potentiale i forhold 
til at individualisere kræftopfølgning til patienter behandlet for hæmatologisk kræft 
og en multidisciplinær tilgang til opfølgning kunne bidrage til en forstærket holistisk 
tilgang til patienternes behov for støtte. Risikoen for forringelse af helbredsrelateret 
livskvalitet som følge af relaps eller progressiv sygdom kunne muligvis adresseres 
ved hjælp af PRO data i forhold til at danne basis for tidligere behandling af 
symptomer og støtte patienterne i fastholdelse af vanlige aktiviteter.  
Fremtidig forskning: Udvikling og implementering af interventioner baseret på PRO 
data bør være forudgået af kvalitative forskningsstudier, der undersøger 
patienternes behov og præferencer i forhold til den planlagte intervention og som 
bidrag til et solidt fundament for fremtidige PRO-baserede interventioner. 
Derudover bør fremtidig forskning undersøge, hvorvidt symptommonitorering 
baseret på PRO data kan medvirke til at stabilisere eller forbedre helbredsrelateret 
livskvalitet hos patienter med relaps eller progressiv hæmatologisk kræft.  
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CHAPTER 1. INTRODUCTION 
1.1. SETTING THE SCENE: HEMATOLOGICAL CANCER 
Hematological cancers are a heterogeneous group of neoplasms defined by disease 
in the bone marrow and the lymph system. The main diagnostic categories are 
lymphomas, leukemias, and plasma cell neoplasms (1). Globally, incidence rates of 
hematological cancers have increased during the past decades, varying among 
continents and countries, with the highest rates in Australia, Western Europe, and 
high-income North America (2–4). The continuing increase in incidence rates is 
mainly the result of population growth, population aging, and changing population 
age structures (2). Studies indicate that more men than women are diagnosed with 
hematological cancer and that older adults are at higher risk of disease than younger 
people (2–4). Although survival has improved with the development of novel 
treatments (5), hematological cancer is often associated with high morbidity and 
mortality (2,3,6) and with secondary primary cancer (7). In 2018, approximately 4000 
people were diagnosed with a malignant hematological disease in Denmark (8). 
Patients with hematological cancer are diagnosed, treated, and cared for at highly 
specialized hematological departments nationwide.  
 
1.2. TRAJECTORY OF HEMATOLOGICAL CANCER 
Hematological cancers follow an overall disease trajectory including diagnostic tests 
and diagnosis of primary disease, treatment of primary disease, and follow-up after 
primary disease. Some patients will experience relapse or progressive disease (9–13) 
for which they may receive treatement. After treatment, the patients may enter 
follow-up, receive additional treatment, or palliative care depending on the outcome 
of treatment for relapsed or progressive disease. Figure 1 illustrates the general 
hematological cancer trajectory.  
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Figure 1: Illustration of the general hematological cancer trajectory 
 
In addition to the general disease trajectory, the individual disease trajectories offer 
a number of different scenarios because of the heterogeneity of hematological 
cancers. The disease trajectory varies according to the specific diagnosis, treatment, 
risk factors, patient characteristics, and number of relapses and episodes with 
progressive disease (9–13). Hematological cancers can be largely divided into two 
groups: disease with an often-aggressive pattern and a high chance of cure, e.g., 
aggressive lymphomas and acute leukemia (9,13); and diseases of a more chronic 
nature e.g., chronic leukemia, indolent lymphoma, and multiple myeloma, which are 
incurable and progress throughout a patient’s life (10–12). For all diseases, 
diagnostic testing and primary disease identification are the first steps on the 
trajectory. During this time, staging and risk assessment are carried out. Following 
diagnostics, a patient may receive treatment with immunotherapy, chemotherapy, 
stem cell transplantation and/or radiation or enter an observational period (watch 
and wait) depending on individual diagnosis, staging, and risk assessment (14–17). 
After treatment for the primary disease,  patients enter survivorship care, which 
focuses on relapse detection and monitoring of adverse events and long-term 
complications. Survivorship care is structured as regularly scheduled follow-up visits 
with physicians at the outpatient clinic, and the interval is based on diagnosis, 
individual risk assessment, and treatment outcome (9,10,12). In case of relapsed or 
progressive disease, the treatment goal is to reach cure or remission. In cases where 
this fails, a patient will be offered further treatment or referred to palliative care. 
Diagnostic tests 
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Hematological cancers and treatment pose various challenges for patients 
throughout the disease trajectory. The health-related challenges occur because of 
the nature of the disease and as a consequence of treatment, adverse events, and 
complications related to treatment (18). The literature indicates that physical, 
emotional, and social aspects of a patient’s life are negatively affected. These 
consequences affect both newly diagnosed patients and patients experiencing 
relapse and can continue long into survivorship (19,20).  
 
1.3. HEALTH-RELATED CHALLENGES ALONG THE 
DISEASE TRAJECTORY 
Patients with hematological cancer face various challenges along the disease 
trajectory. From onset of treatment and into survivorship, these patients describe 
unmet supportive care needs. Research shows that psychosocial needs, fear of 
recurrence, and informational needs are among the needs that patients expect 
health professionals to recognize during the disease trajectory (21–25). Although 
unmet needs are reported throughout the trajectory, it seems that survivors of 
hematological cancer particularly experience them. One of the consequences of not 
being supported during the transition from active disease into survivorship has been 
described as living without a safety net after cancer diagnosis and treatment (22,26). 
In addition to the consequences of unmet needs, research has established an 
association between unmet needs and impaired quality of life (QoL) and various 
areas of functioning. Finally, unmet needs may cause emotional distress (27–29). 
It is well established that hematological cancers and their treatment have an overall 
negative effect on patient QoL throughout the disease trajectory (19,30–33). Various 
dimensions of QoL are affected, one of which is the physical dimension. Patients with 
hematological cancer suffer from physical symptoms such as pain, fatigue, and sleep 
disturbance. Furthermore, physical functioning, such as carrying out daily activities, 
is affected (19). Various degrees of anxiety and depression as well as social, cognitive, 
and role functioning have been detected as affected dimensions (34–37). Impaired 
QoL has been documented throughout the disease trajectory, from treatment for 
primary diagnosis to relapse situations to follow-up and long into survivorship 
(19,20,38,39). The literature makes it evident that hematological cancer particularly 
negatively affects survivors and patients who experience relapse. Hence, the 
following section contains a review of studies related to supportive care needs and 
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QoL within the context of survivors of hematological cancer and those who 
experience relapse.  
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CHAPTER 2. STATE OF THE ART 
A systematic literature search was conducted to identify current scientific knowledge 
and potential gaps in the scientific literature in relation to unmet supportive care 
needs in survivors of hematological cancer and QoL in those who experience relapse. 
The literature search was carried out in cooperation with a research librarian. 
PubMed and CINAHL were searched using relevant search terms such as 
“Hematological Neoplasms,” “Lymphoma,” “Leukemia,” “Multiple Myeloma,” 
“Survivorship Care,” “Patient-reported outcomes,” “Quality of life,” “Relapse,” and 
“Recurrence.” 
2.1. SURVIVORSHIP CARE 
The term “cancer survivor” is defined in a variety of ways, but the most widely used 
definition is that being a cancer survivor is a process that begins at diagnosis and 
continues through the balance of life (40). However, when reporting on cancer 
survivors, many authors choose a context-specific definition of survivorship based 
on the study sample (40). In the context of this PhD thesis, a cancer survivor is 
defined as a patient who has ended treatment for primary disease or relapse and 
entered follow-up as part of survivorship care, because these are the characteristics 
of the patients studied. 
Patients with hematological cancer report unmet supportive care needs during the 
disease trajectory, with an emphasis on psychological needs (21–26,28,41–47). 
Psychological needs relate to a desire or requirement for help or support that 
underlies a person’s emotional psychological well-being. The literature review makes 
it evident that fear of recurrence is among the most predominant unmet needs for 
patients with hematological cancer (21,22,24,48–50). Furthermore, these patients 
report unmet needs in relation to the transition from active treatment to 
survivorship care (26,47,51,52). This transition is described as “living without a safety 
net” and “adjusting to a new normal” after cancer diagnosis and treatment (22,52). 
Information related to prognosis, managing and coping with side effects, lack of 
clarity regarding treatment decision making, and uncertainty about the future have 
also been reported as areas of unmet needs (21,23,26,44,49–51,53). Hence, 
insufficient support presents patients with challenges in dealing with issues related 
to the disease and what happens after treatment ends. In addition, unmet 
supportive care needs are associated with an impairment in QoL. A Danish 
population-based study examined a mixed population of patients with cancer, 
including patients with lymphoma, and found that unmet needs were associated 
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with impaired QoL and increased psychological distress (27). These results are 
supported by those of Oberoi et al. (2017), who found that unmet supportive care 
needs during treatment in a group of patients with hematological cancer were 
associated with impaired QoL in terms of physical and emotional well-being (28,29). 
Based on the existing literature, current survivorship care appears to be unsuccessful 
in terms of meeting the needs of patients with hematological cancer.  
 
2.1.1. NURSE-LED SURVIVORSHIP INTERVENTIONS 
During the past decades, nurse-led interventions have been introduced to enhance 
the quality of survivorship care and address the psychosocial and informational 
needs of patients. Moreover, nurse-led interventions may contribute to ease the 
workload within busy outpatient clinics. A variety of nurse-led interventions have 
been developed and tested in a number of cancer populations (54–78). The most 
predominant cancer diagnoses within the literature in this area are colorectal 
(56,57,60,61,64,74,77), prostate (59,62,67,72,76), and breast cancer (69,73,78). 
Some interventions have been designed to provide alternating physician and nurse-
led consultations(54,72), whereas others have replaced physician visits with nurse-
led clinics, either substituting physician visits with nurse-led consultations or adding 
consultations to the usual care program (58,79). Some interventions have been set 
in-hospital, and others have been telephone-based. Most interventions have relied 
on patient interviews that elicit information about the patient’s health. Studies show 
that nurse-led survivorship interventions are well-accepted by patients (80,81) and 
suggest that most patients find nurse-led telephone consultations convenient and 
personalized (82–84). Furthermore, nurse-led interventions have been found to 
meet cancer patients’ psychological and informational needs (85). Although findings 
are mixed, nurse-led survivorship interventions may reduce cancer symptoms and 
emotional distress and improve health-related QoL (HRQoL) and self-care (81,86).  
 
2.1.2. NURSE-LED INTERVENTIONS IN HEMATOLOGY 
Although a comprehensive knowledge base on nurse-led survivorship interventions 
exists, few studies have been conducted in hematological settings. Taylor et al. 
(2019) conducted a pragmatic randomized controlled trial, assigning survivors of 
lymphoma to either usual care or a nurse-led lymphoma survivorship clinic (87). 
These authors found that the survivorship clinic group reported fewer unmet needs, 
less distress, and an increase in empowerment compared with the control group, 
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although the differences were not statistically significant (87). In a pilot study, 
Overend et al. (2008) tested a nurse-led telephone intervention in survivors of 
hematological cancer with indolent and chronic malignancies and found that nurse-
led telephone consultations were safe and efficient and associated with a high level 
of patient satisfaction (88). Compaci et al. (2015) tested a model for an early 
trajectory survivorship follow-up of patients with lymphoma. Their findings 
suggested that alternating general practitioner visits and nurse-led telephone 
consultations was an efficient and patient-accepted alternative to standard follow-
up (89). Finally, John et al. (2013) tested the feasibility of a nurse-led survivorship 
intervention for patients with lymphoma who were 3 years post-treatment and in 
complete remission. As an alternative to the usual in-hospital visits with physicians, 
the participants were offered 30-minute in-hospital visits with a nurse (79). These 
authors found that the patients were as satisfied or more satisfied with the nurse-
led clinic than with usual care (79). Thus, nurse-led survivorship care may be feasible 
and well-accepted among patients with hematological cancer, and this alternative 
survivorship care model may meet patient needs and increase patient 
empowerment to a higher degree. However, two of the four studies were designed 
as in-hospital consultations, resulting in additional workload for nurses and 
additional scheduled in-hospital visits, which may not fit well with today’s 
increasingly busy outpatient clinics. John et al. (2013) raised this point, noting that 
the intervention placed a significant strain on nurse workload and acknowledging 
that this model may not be feasible because of the growing number of outpatients 
(79). Furthermore, all four studies were based on interviews performed by the nurse 
with the aim of eliciting information about the patient’s health state (79,87–89). 
However, the present health issues might be more efficiently approached if both 
patient and nurse were prepared before the consultation, and preparation might 
increase the efficiency of the use of the time while further enhancing the quality of 
the consultations. Research shows that use of patient self-report about self-
perceived health status in terms of QoL, functioning, and symptoms —in other words 
patient-reported outcome measures (PROs) — can be beneficial when applied as a 
screening and dialogue tool in clinical practice (90). Thus, PROs may be valuable as a 
tool in the follow-up of patients with hematological cancer and may contribute to a 
more efficient and targeted consultation.  
 
2.2. QUALITY OF LIFE 
QoL is an important parameter in understanding the impact of cancer treatment and 
is increasingly used as clinical outcome in cancer trials (91). Using QoL as a clinical 
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outcome has come into focus during the last decades as healthcare systems and 
healthcare professionals increasingly have become aware of the importance of 
adding the patient perspective to clinical research (92,93). QoL is ill defined, and a 
uniform definition may be elusive because it means different things to different 
people (94). In the literature, there is a distinction between QoL and HRQoL. HRQoL 
has been defined as a patient’s self-perceived health status and is argued to relate 
to the way health affects the overall QoL (95). Osoba et al. provided this often-used 
definition of HRQoL, writing that it “ … is a multidimensional construct encompassing 
perceptions of both positive and negative aspects of dimensions such as physical, 
emotional, social, and cognitive functions, as well as the negative aspects of somatic 
discomfort and other symptoms produced by a disease or its treatment” (96). 
Based on that argument and definition, I propose in this thesis that the role of HRQoL 
in the context of the primary aim of health professionals is to alleviate symptoms 
and care for patients in response to how the disease affects QoL and ultimately the 
patient’s life (97).  
2.2.1. HRQOL IN PATIENTS WITH HEMATOLOGICAL CANCER 
Patients with hematological cancer experience impaired HRQoL during the disease 
trajectory (19,20). Numerous clinical studies have reported on HRQoL in patients 
with hematological cancer as a secondary or even tertiary endpoint with the aim of 
determining how drugs affect HRQoL (98–102). However, longitudinal observational 
and cross-sectional studies assessing HRQoL independent of treatment have 
established that patients with hematological cancer experience an overall negative 
effect on HRQoL at all disease stages (19,20,36,38,39,103,104). The physical 
dimensions of HRQoL are affected in terms of symptoms such as pain, fatigue, 
nausea, vomiting, insomnia (37,105), difficulties with concentration, and sleep 
disturbance (19,36), as well as in terms of reduced daily physical activity (106). 
Hematological disease also has been reported to negatively affect psychological 
dimensions (36,37,107) as well as role and social functioning in terms of relations 
and impaired functioning in daily activities (37). 
Patients with recurrent hematological disease seem to be more likely to experience 
impaired HRQoL compared to those with a recent diagnosis of primary disease (103–
105). When these patients relapse, their situation worsens because potential 
treatment resistance poses a risk of overtreatment (108). This complex health 
challenge is being addressed as researchers seek to target treatment according to a 
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patient’s genomic profile, known as precision medicine (109). Despite great progress 
in precision medicine, relapse continuously poses a challenge in clinical decision 
making, and physicians often cannot ensure a treatment effect, improvement, or 
stabilization in HRQoL. Thus, identification of patients who deteriorate as a result of 
relapse treatment would offer health professionals an evidence base for treatment 
decisions and patient guidance. However, the literature on HRQoL in patients with 
relapsing hematological disease is limited, so that evidence-based clinical decision 
making is challenging in terms of guiding patients toward the best treatment 
solution. Studies of HRQoL in patients with hematological relapse are either clinical 
studies, with highly selected study populations, making the results difficult to apply 
to population-based clinical practice (110–112), or are predominantly part of a 
combined investigation into HRQoL in patients in different hematologic disease 
states (103,104,113). Given these gaps, knowledge about HRQoL during relapse 
treatment is important for informing clinical decision making and optimizing 
treatment and care for patients experiencing relapse. 
 
2.3. PATIENT-REPORTED OUTCOMES 
In recent decades, PROs have been increasingly used in clinical practice and research 
because they have proven valuable in terms of introducing the patient perspective 
into healthcare (114,115). PRO is defined as a measurement based on “any report of 
the status of a patient’s health condition that comes directly from the patient, 
without interpretation of the patient’s response by a clinician or anyone else” (116). 
Thus, PROs represent the patient perspective on personal health status without 
outside interpretation and have been used extensively to elicit these perspectives 
(20,30,39). Although in clinical practice, PROs have the potential to enhance patient-
centered care (PCC), their implementation needs to be carefully considered (114). A 
review of the options and considerations regarding this implementation noted that 
implementing routine PRO assessment involves a number of methodological and 
practical decisions such as identifying the goals for collecting PROs and determining 
relevant PRO measures (90,117). 
 
2.3.1. PRO IN NURSE-LED CONSULTATION 
PROs have been used as a screening tool during treatment and follow-up of cancer 
patients (118,119). Studies show that PROs have the potential to improve patient–
clinician communication and to contribute to better symptom management 
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(117,120,121). Introducing PROs into survivorship care of patients with 
hematological cancer as a dialogue tool in combination with nurse-led interventions 
could be assumed to enhance quality of care. Furthermore, nurse-led survivorship 
interventions in combination with PROs could address the supportive care needs of 
patients in terms of psychological and informational needs, which are often not fully 
supported (21).  
 
2.3.2. PRO TO MEASURE HRQOL OVER TIME 
HRQoL is an important parameter in understanding the impact of cancer treatment, 
and assessment of HRQoL in patients with cancer is now conceptually viewed as an 
important complement to traditional objective evaluation measures such as survival 
and time to remission (122). Furthermore, identifying patients who are at risk of 
experiencing HRQoL deterioration during treatment may assist healthcare 
professionals in individualizing and targeting treatment and supportive care (123). 
Thus, applying PROs to measure HRQoL in patients with hematological disease may 
provide clinicians with the patient perspective of self-perceived health state, offering 
clinicians an important and central tool for providing patient–centered treatment 
and care (124). 
 
2.4. PATIENT-CENTERED CARE 
In recent decades, PCC has been a focus in western healthcare systems because of 
evidence that it can improve quality of care, patient outcomes, and cost 
effectiveness (125–127). PCC can be defined as: “a partnership among practitioners, 
patients, and their families (when appropriate) to ensure that decisions respect 
patient’s wants, needs, and preferences and that patients have the education and 
support they need to make decisions and participate in their own care” (125,128). 
As such, PCC is an approach to offering high-quality healthcare by inviting the patient 
to be an active partner in decision making about their health in ways that are 
consistent with the patient’s needs and preferences (129,130). 
 
In the context of this PhD thesis, providing PCC may help support patients with 
hematological cancer who have unmet supportive care needs and to target 
survivorship care towards the patient’s individual needs. Additionally, measuring 
HRQoL at the group level using PROs may be considered within the frame of PCC as 
eliciting a patient’s self-perceived health status to inform clinical practice. This 
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information may assist in providing better symptom management as well as in 
supporting patients managing functional problems. Thus, with the main objective of 
collecting information about patients’ self-perceived health state, PROs may be 
considered a tool to facilitate PCC in patients with hematological disease. 
In the literature, person-centered care and PCC are used seemingly interchangeably, 
and there are similarities; however, the term “person-centered care” is broader 
because the aim is to facilitate a meaningful life, whereas the aim for PCC is to reach 
a functional life (131). In this context, PCC is used here because the research 
encompasses patients with cancer who are linked to the health system by ongoing 
treatment and care.  
 
 
2.5. RATIONALE FOR FURTHER RESEARCH 
In summary, patients with hematological cancer report unmet supportive care needs 
and impaired HRQoL throughout the disease trajectory (20–23,30,106). These 
challenges pose a complex health problem for patients as well as health systems. 
Patients with hematological cancer are in a vulnerable and life-threatening position, 
and although health professionals work hard to treat and care for this patient group, 
research demonstrates that health professionals to some extent are unsuccessful in 
terms of meeting patient needs and ensuring patient HRQoL (21).  
 
Research has established that nurse-led cancer survivorship interventions are 
feasible in terms of addressing the supportive care needs of patients, and these 
interventions are well-accepted by patients (80,81). Implementing PROs in clinical 
practice, i.e., as part of outpatient follow-up, has proved successful in facilitating 
targeted healthcare and promoting patient involvement (90,132). Thus, nurse-led 
interventions and PROs independently contribute to PCC by targeting unmet needs 
and involving patients in their treatment and care during the disease trajectory. 
However, it is not known whether the quality of cancer survivorship care to patients 
treated for hematological cancer could be improved by combining the two elements 
through nurse-led telephone consultations based on pre-collected PROs. This 
approach might have the potential to further target care and increase patient 
involvement. Assessing this potential requires the development and testing of 
interventions that address individual patient needs, as well as insight into the 
experiences of patients who participate in such interventions. Learning about their 
experiences may provide a deeper understanding of the aspects that are most 
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important to them, facilitating further development of interventions based on their 
experiences.  
It is pivotal to address supportive care needs during survivorship because unmet 
need can lead to impaired QoL. Patients with hematological cancer experience 
impaired HRQoL throughout the disease trajectory, and those who experience 
relapse report worse HRQoL than newly diagnosed patients or cancer survivors (19). 
Because of the risk of treatment resistance resulting in overtreatment, the relapse 
situation is challenging in terms of clinical decision making and patient guidance. 
Moreover, physicians often cannot ensure stabilization or improvement in HRQoL 
during relapse treatment. Identifying patients who may deteriorate as a result of 
relapse treatment would be valuable in tackling this dilemma, informing shared 
decision making to facilitate PCC. Conclusively, there is a dearth in the literature 
regarding nurse-led survivorship interventions with survivors of hematological 
cancer and HRQoL research in patients with relapsed or progressive disease. Thus, 
this research is important and highly needed as patients with hematological cancer 
face a variety of challenges along the disease trajectory.  
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CHAPTER 3. THE OVERALL AND SPECIFIC AIMS 
FOR THIS PHD THESIS 
The overall aim of this PhD thesis was to examine the potential of PROs among 
patients with hematological cancer along the disease trajectory and to determine if 
PROs could facilitate patient-centered care and contribute to increased quality of 
care in this population.  
3.1. SPECIFIC AIMS 
The PhD thesis consists of three studies that aimed to: 
• investigated the feasibility of a shared care follow-up initiative based on 
alternating standard physician visits and nurse-led telephone consultations 
supported by PRO in patients with B-cell neoplasms. (Study I) 
• to explore hematological cancer survivors’ experiences of participating in a 
shared care follow-up based on alternating physician visits and nurse-led 
telephone consultations. (Study II) 
• to identify patients who experienced deterioration in HRQL after relapse 
treatment and to investigate HRQL patterns in a cohort of hematological 
cancer patients with relapse or progressive disease. (Study III) 
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CHAPTER 4. RESEARCH DESIGN AND 
METHODS 
This chapter includes a description of the overall research design of the PhD thesis 
as well as a description of methods presented in paper I, II and III (133–135). 
 
4.1. MULTI-METHOD RESEARCH DESIGN 
The overall research design of this PhD thesis is a multi-method design including 
three studies. Multi-method design is a research approach in which both 
quantitative and qualitative methods are used to answer the study questions 
(136,137). In this PhD thesis, multi-method research design was chosen because 
both quantitative and qualitative methodologies and data sources were needed to 
sufficiently investigate the potential of PROs during the hematological disease 
trajectory (136). The assumption was that this approach would generate a deeper 
understanding of the studied topic in terms of addressing the complex health 
situation in which patients with hematological cancer find themselves during 
treatment and survivorship. In addition, findings from each method were assumed 
to complement each other and strengthen the research to answer the overall aim. 
The three studies and their interconnection are displayed in Figure 2. As indicated by 
the double arrow, Figure 2 shows how Study I and Study II are interconnected, 
investigating a shared care follow-up initiative by examining the feasibility and 
exploring patient experiences, thus eliciting knowledge from two perspectives using 
two research methods. The single arrow illustrates that the results from each study 
and their interconnection will be addressed in a joint discussion, comparing and 
contrasting the results with each other and in the context of existing research. 
 
A multi-method approach offers advantages in terms of the potential to accentuate 
distinctive aspects of the studied field as well as eliciting a deeper understanding 
through use of quantitative and qualitative data sources (136,137). However, 
limitations of this research design also have been accentuated because applying both 
methods is time consuming and requires the researcher to have a certain level of 
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All three studies were conducted at the Department of Hematology, Aalborg 
University Hospital, Denmark.  
 
  









Joint discussion of results 
against the overall aim
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4.3. STUDY I 
The description of Study I is based on the paper entitled, “Shared care follow-up of 
patients with B-cell neoplasms based on nurse-led telephone consultations and PRO-
Data: A feasibility study from the North Denmark Region” (133). 
 
4.3.1. DESIGN 
Study I was a feasibility study with the aim to investigate the feasibility of a shared 
care follow-up initiative based on alternating standard physician visits and nurse-led 
telephone consultations supported by PRO in patients with B-cell neoplasms. 
 
4.3.2. STUDY POPULATION AND RECRUITMENT 
Patients receiving ongoing post-treatment follow-up after B-cell treatment were 
eligible for inclusion. The inclusion criteria were “(a) ≥18 years; (b) diagnosed with B-
cell neoplasms (chronic lymphocytic leukemia and lymphomas); (c) disease in 
remission or stable without treatment initiatives for at least six months prior to 
inclusion; and (d) sufficient self-care to report new symptoms and willingness to 
return PRO measures on a regular basis”. Exclusion criteria were a) conditions 
requiring close medical attention; b) conditions which compromised the 
comprehension of the study aim (e.g. dementia); and c) inability to complete 
questionnaires online (133). The patients were recruited during in-hospital routine 
follow-up visits with the attending physicians specialized in hematology and in B-cell 
disease particularly. The sample size was reached using a convienice sampling 




4.3.3. FOLLOW-UP STRUCTURE 
The patients were assigned to alternating standard routine follow-up with their 
attending physician at the hematological outpatient clinic and nurse-led telephone 
consultations. The nurse-led telephone consultations were scheduled ad hoc 
replacing every second physician visit. Prior to all consultations, blood samples were 
taken and approved by the attending physician. The interval for the follow-up was 
individualized depending on diagnosis, time since treatment, disease-related risk 
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factors, and individual assessments made by each patient’s responsible physician 
(133). 
 
4.3.4. DATA COLLECTION 
4.3.4.1 Data collection instruments 
PRO data were collected using the European Organization for Research and 
Treatment of Cancer EORTC-QLQ-C30 (EORTC-QLQ-C30) (139), Myeloproliferative 
Neoplasm – Symptom Assessment Form (MPN-SAF) (140), Hospital Anxiety and 
Depression Scale (HADS) (141). The PRO measures are presented in Table 1.  
 
Table 1: Description of patient-reported outcome measures used in a shared care follow-up initiative in 
patients with B-cell cancer (133) 





Cancer - EORTC 
QLQ-C30 (139) 
Health-related 
quality of life 
30-item cancer-specific questionnaire consisting 
of 15 domains 
• one global quality of life (QoL) scale 
• five functional domains (physical, role, 
emotional, cognitive, and social 
functioning) 
• nine symptom domains (fatigue, nausea 
and vomiting, pain, dyspnea, insomnia, 




Scale – HADS (141) 
Anxiety and 
depression 
14-item anxiety and depression questionnaire 
consisting of 2 scales 
• Anxiety (HADS-A) 






Symptoms 17-item symptom scale developed to measure 




• TSS (“worst fatigue” from the BFI plus nine 
items from the MPN-SAF – concentration, 
early satiety, inactivity, night sweats, 
itching, bone pain, abdominal discomfort, 
weight loss, and fever) 
 
The MPN-SAF was chosen because no lymphoma-specific PRO measure was available 
in Danish at the time the study began. Four ad hoc questions were developed in 
collaboration with consultants specialized in B-cell cancer to cover lymphoma-
specific symptoms (133). The ad hoc questions are presented in Table 2.  




Table 2: Ad hoc questions added to the MPN-SAF to cover B-cell neoplasm–specific symptoms associated 
with recurrent disease (133) 
Have you since last consultation: 
Noticed swollen lymph nodes? Yes: No: 
Had infections that demanded antibiotic 
treatment? 
Yes: No: 
Experienced the same symptoms as last 
time you were ill from your blood disease? 
0 (No) 1 2 3 4 5 6 7 8 9 10 (Yes) 
Do you feel ill from your blood disease? 0 (No) 1 2 3 4 5 6 7 8 9 10 (Yes) 
 
The survey of the patients willingness to and perception of completing  PRO 
measures as part of follow up was conducted using the Patient Feedback Form (PFF) 
(142,143).  
 
4.3.4.2 Data collection procedure 
The patients responded to electronic PRO measures prompted by email invitations 
sent 7 days before scheduled consultations, with a request to complete them 3 days 
before the appointment. The PRO data were collected through an online IT platform 
hosted by Dansk Telemedicin A/S. 
The nurse-led telephone consultations were based on analysis of the collected PRO 
data. Prior to any consultation, the nurse analyzed the PRO data using the calculated 
scores as well as an assessment of any changes in scores between consultations 
(144–146). If needed, an in-hospital nurse consultation was arranged, or 
alternatively, the patient was offered a visit with the physician (133). 
 
A cross-sectional survey of patient acceptability with completing PRO measures as 
part of the follow-up was conducted in between November 2018 and March 2019, 
inviting all included patients. Data was collected using RedCap, which is a secure web 
platform for building and administering surveys (147). The survey was conducted 
anonymously to prevent potential response bias (133,148).  
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4.3.5. STATISTICAL ANALYSIS 
Descriptive statistics were used to assess the feasibility, calculating recruitment rate, 
response rate, dropout rate, and patient acceptability with completing PRO 
measures as part of clinical practice. (133). 
  
4.3.6. ETHICS 
Participation was voluntary, and the patients gave oral and written consent prior to 
inclusion. The study was approved by the national Data Protection Agency (jour. no. 
2008-58-0028). According to Danish law, the study was exempt from formal ethical 
approval (133).  
 
4.4. STUDY II 
The description of Study II is based on the paper entitled, “Hematological cancer 
survivors’ experiences of participating in a shared care follow-up – an exploratory 
interview study (134). 
 
4.4.1. DESIGN 
Study II was a qualitative interview study with the aim to explore hematological 
cancer survivors’ experiences of participating in a shared care follow-up based on 
alternating physician visits and nurse-led telephone consultations.  
 
4.4.2. STUDY POPULATION AND RECRUITMENT 
Eligible participants for Study II had participated in the feasibility study. In total, 12 
patients were included, and the study population was sampled based on the concept 
of purposeful sampling to ensure maximum variation (149). Maximum variation was 
chosen “to capture a wide range of perspectives and elicit common patterns across 
the patient experience” (134). Sampling was based on patient characteristics such as 
age, sex and diagnosis. Furthermore, the participating patients had undergone at 
least two nurse-led telephone consultations, meeting a certain level of experience 
with the shared care follow-up. The patients were recruited by telephone, and 
written information and consent forms were forwarded by email or postal service 
(134). 
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4.4.3. DATA COLLECTION 
Data were collected through one-on-one interviews based on a semi-structured 
interview guide (150). This guide was chosen to elicit the patient experience and 
allow for a dynamic yet systematic approach to the interviews (134,150). 
 
4.4.3.1 Data collection instrument 
The semi-structured interview guide was developed based on the seven phases of 
an interview study, as presented by Kvale and Brinkmann (151). The interview guide 
covered the research topics in question, such as experience of the shift from regular 
follow-up to shared care follow-up, completing PRO measures as part of follow-up, 
and the patients’ perception of talking to a nurse as part of follow-up (134).  
 
4.4.3.2 Data collection procedure 
The interviews were conducted face-to-face at the patients’ homes and at Aalborg 
University Hospital research facilities. The interviews lasted 45–90 minutes, were 
recorded on a mini-recorder, and were subsequently transcribed. It was estimated 
that interviewing 12 patients would be sufficient to meet the point of data 
saturation, defined as the point at which further data collection would not lead to 
further new knowledge (134,152). The interview guide is presented in Appendix E. 
 
4.4.4. DATA ANALYSIS 
Thematic analysis was used to analyze the data (153). Initially, the transcribed data 
were openly coded using descriptive coding to elicit common codes throughout the 
dataset. Next, the data were re-coded with the intention of identifying categories 
and themes across the dataset (154). The reliability of the analysis process was 
established through repeated dialouge among the authors. The data set would be 
re-consulted in case of divergence and until general agreement was reached 
(134,154). Furthermore, validity was pursued by presenting positive as well as 
discrepant data derived from the data material (155). The analysis was aided by 
NVivo qualitative analysis software (156). 
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4.4.5. ETHICS 
Prior to the interviews, the patients signed a written consent form. During data 
analysis and reporting of findings, the patients were identified and thereby 
anonymized by project identification numbers to secure potential identification of 
the patients. The study was approved by the Danish Data Protection Agency (jour. 
no. 2008-58-0028). Approval from the National Ethics Committee was not required 
according to Danish legislation (134). 
 
4.5. STUDY III  
The description of Study III is based on the paper entitled, “The use of patient-
reported outcomes in precision medicine and hematological patients with relapse or 
progressive disease: a longitudinal observational study” (135).  
 
4.5.1. DESIGN 
The study was a longitudinal, observational population-based study with the to 
identify patients who experienced deterioration in HRQL after relapse treatment and 
to investigate HRQL patterns in a cohort of hematological cancer patients with 
relapse or progressive disease. 
 
The study was a sub-study of a prospective, non-interventional population-based 
clinical study with the aim “to describe genetic alterations in tumors from 
hematologic relapse patients and hence explore the potential of precision medicine” 
(ProGen/ProSeq) (108,109,135). The clinical study has been ongoing at the 
Department of Hematology, Aalborg University Hospital, since 2016. 
 
4.5.2. STUDY POPULATION AND RECRUITMENT 
Eligible patients were recruited by study nurses connected to ProGen/ProSeq. The 
details of recruitment and workflow have been reported in detail by Bødker et al. 
(2020) (108). The study population consisted of patients age ≥18 years with 
hematological cancer and with pathologically verified relapsed or progressive 
disease. Patients were excluded in case of non-response to the baseline 
questionnaire and subsequent relapse during the study period. 
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4.5.3. DATA COLLECTION 
The data collection was carried out using PRO measures and extraction of clinical 
data from electronic health records. 
 
4.5.3.1 PRO measures 
The PRO data were collected using the EORTC-QLQ-C30 and HADS (141,157). These 
PRO measures were described in detail in Section 4.3.4.1. 
 
4.5.3.2 Data collection procedure 
The time points for PRO data collection were set to baseline and 3, 6, 9, and 12 
months, respectively, and baseline was defined as the point of verification of 
diagnosis of relapsed or progressive disease. The PRO measures could be completed 
either online or in hard copy. Online PRO measures were administered via REDCap 
survey tool (147) and links to the online PRO measures were sent via email. In case 
of non-response to the PRO measures, a reminder was sent after 7 days and 
subsequently after 14 days in case of continuous non-response. If the patients chose 
to complete the PRO measures in hard copy, they would receive the PRO measures 
by post including a pre-stamped return. No reminders were sent because postal 
delivery time taken into account would affect the real-time data collection (135).  
 
4.5.4. ANALYSIS  
Descriptive statistics were used to describe patient characteristics, response, and 
dropout rates. Patients were categorized based on treatment strategy: curative-
intent treatment (CIT) and non-CIT. HRQoL domain scores were scored according to 
developers’ guidelines (144,146), and missing data in EORTC-QLQ C30, were 
managed according to developers’ guidelines (144), and for HADS, guidelines by Bell 
et al. (2016) were applied because no guidelines are available from the developers 
(135,158). 
 
The PRO data were analyzed on the patient level to identify the proportion of 
patients reporting moderate and severe symptoms or functional problems at 
baseline and at 12 months of follow-up. The thresholds for severe and moderate 
symptoms and functional problems in the EORTC-QLQ-C30 were based on thresholds 
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defined in existing research in patients with hematological cancers (37,39). For 
HADS, presence of anxiety or depression was based on the thresholds presented by 
the developers (146). A responder analysis was carried out to identify the number of 
patients experiencing either improvement or deterioration in HRQoL domains 
assessing each patient’s individual score change from baseline to 12 months of 
follow-up (159). Finally, Fischer’s Exact test was used to test potential correlations 
between baseline characteristics and deterioration in HRQoL domains (135) .  
 
At the group level, the baseline mean scores for EORTC-QLQ-C30 and HADS (160) 
were calculated, and the difference from baseline to 12 months for each HRQoL 
domains was calculated, fitting the HRQoL scores as linear mixed models (161). 
Finally, clinically relevant differences from baseline to the 12-month follow-up, were 
calculated using Cocks’ guidelines for interpreting change in scores for the EORTC-
QLQ-C30 were  (162), and the threshold for clinically meaningful change in HADS was 
based on distribution-based minimum important differences of standard errors of 
measurement (163). The significance level was set to 95%. The statistical analyses of 
the PRO data were carried out in R (135,164).  
 
4.5.5. ETHICS 
The patients signed a consent form before entering the study. The study was 
approved by the Danish Data Protection Agency (Jour. No. 2008-58-0028) as well as 
the Ethical Committee of North Denmark (N-20150042) (135).  
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CHAPTER 5. RESULTS 
The results are presented in relation to each study, and the study aim is presented 
to optimize readability. For further elaboration on the results, please consult Paper 
I, Paper II, and Paper III (133–135). 
 
5.1. STUDY I 
Aim: to investigate the feasibility of a shared care follow-up initiative based on 
alternating standard physician visits and nurse-led telephone consultations 
supported by PRO in patients with B-cell neoplasms. 
 
Results (133): Between February 2017 and June 2018, we included 80 patients with 
B-cell disease. The inclusion process is illustrated in Figure 3. The baseline 
characteristics of the patient population including age, diagnosis, time since 
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Figure 3: Flowchart illustrating the inclusion process and number of excluded patients, grouped by reasons 
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Table 3: Baseline demographic, treatment, and follow-up characteristics of patients with B-cell neoplasms 
and assessed as being in remission or stable without treatment initiatives 6 months prior to inclusion 
(n=80) (133) 








N 15 17 48 80 
Female 8 3 27 38 
Male 7 14 21 42 
Age, median 70.0 69.0 68.0 68.0 
Age, range 37.0–82.0 58.0–78.0 28.0–81.0 28.0–82.0 
Number of visits at 









































2-3 months 9.0 7.0 18.0 34.0 
4-5 months 4.0 3.0 18.0 25.0 
6 months 2.0 7.0 12.0 21.0 
Number of treatment lines 
1 13.0 5.0 30.0 48.0 
2 1.0 1.0 2.0 4.0 
>2 0.0 0.0 4.0 4.0 
No previous treatment 
(watch and wait) 
0.0 10.0 12.0 22.0 
¶Curative lymphoma: diffuse large B-cell lymphoma;  Hodgkin lymphoma; §Chronic lymphocytic 
leukemia); ¥Indolent lymphoma: follicular lymphoma, lymphoblastic lymphoma, mantle cell lymphoma, 
marginal cell lymphoma, Waldenstrom macroglobulinemia 
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5.1.1. PATIENT ADHERENCE 
In total, 5 (5/80 [14.7%]) patients chose to leave the study, citing the following 
reasons: number of questions asked (n=1), impaired eyesight leading to difficulties 
reading PRO measures (n=1), and preference of regular hospital follow-up (n=3) 
(133). Furthermore, eight patients (8/80 [10%]) left the study because of relapse 
(n=3), mental health issues (n=1), infections unrelated to the hematological cancer 
(n=2), suspicion of relapsed disease (n=1), and terminal secondary cancer (n=1) 
(133). 
 
5.1.2. NURSE-LED TELEPHONE CONSULTATIONS 
In total, 129 nurse-led telephone consultations were carried out. Proportions of 
conducted consultations were distributed as follows (133): 
 
• 46 patients (46/80 [57.5%]) received ≥1 nurse-led telephone consultation 
without additional intervention; 
• 34 patients (34/80 [42.5%]) were discussed with the physician because of 
questions raised based by blood count or PRO measures;  
• 5 (5/80 [14.7%]) patients were booked for an extra visit with their attending 
physician; 
• No patients were booked to a nurse visit at the outpatient clinic; and  
• 124 (124/129 [96.1%]) nurse-led telephone consultations took place, 
substituting for the same number of regular in-hospital visits 
 
5.1.3. PATIENT ACCEPTABILITY SURVEY 
In total, 59 (59/79 [75%] patients completed the Patient Feedback Form (one patient 
died before study start, so n=79). The survey study demonstrated that completing 
PRO measures as part of follow-up led to the following (133): 
• It was easier for the patients to remember symptoms and side effects when 
speaking to healthcare professionals (50/57 [88%]); 
• The communication with the healthcare professional improved as a result 
of completing PRO measures (51/57 [90%]); and 
• The patients felt involved in their treatment (48/56 [86%]). 
The proportions are based on the sum of the responses of “strongly agree” and 
“agree” in the patient feedback survey.  
 
CHAPTER 5. RESULTS 
45 
5.2. STUDY II 
Aim: to explore hematological cancer survivors’ experiences of participating in a 
shared care follow-up based on alternating physician visits and nurse-led telephone 
consultations. 
 
Findings (134): In total, 12 patients were recruited and interviewed. Patient 
characteristics are presented in Table 4 (134). 
 
Table 4: Characteristics of patients with hematological malignancies included in the interview study of 
their experience with participation in a shared care follow-up based on alternating physician visits and 
nurse-led telephone consultations (134) 
Characteristic N (%) 
Sex  
  Male 6 (50) 
  Female 6 (50) 
Age    
   Median (range)                              64 (53-79)  
Diagnosis  
  DLBCL Ɨ 2 (17) 
  FL ǂ 5 (42) 
  CLL § 1 (8) 
  MZL ¶ 4 (33) 
Treatment  
Chemotherapy 9 (75) 
WAW ŧ 3 (25) 
Marital status  
Living alone 4 (33.5) 
Married/co-habiting 7 (58) 
Married/co-habiting, with children 1 (8.5) 
Job situation  
Employed 6 (50) 
Unemployed/retired 6 (50) 
ƗDLBCL – diffuse large B-cell lymphoma; ǂFL – follicular lymphoma; §CLL – chronic lymphocytic leukemia; 
¶ MZL – marginal zone lymphoma; ŧWAW – watch and wait 
 
5.2.1. THEMES AND KEY FINDINGS 
The thematic analysis yielded in five themes: “fewer visits to the hospital”, “feeling 
secure”, “the value of completing PRO measures”,” nurse consultations”, and “using 
the telephone” (134). The themes and findings are presented in Table 5.  
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Table 5: Themes and findings from the qualitative interview study with the aim of eliciting patient 
experiences of participating in a shared care follow-up program (SCFU) (134) 
Themes Findings 
Fewer visits to the hospital 
 
SCFU seemed to:  
• Offer convenience, 
• Entail less travel and less preparation, and 
• Lead to fewer encounters with other patients 
with cancer and this less experience of anxiety. 
For a minority of the patients, SCFU: 




 SCFU seemed to uphold a sense of security because: 
• Patients saved time without compromising the 
feeling of security, 
• They always had the possibility of contacting 
the clinic or booking an extra visit, and 
• It was believed that the nurse would contact 
the physician if anything needed further 
investigation. 
The value of completing PRO 
measures 
 
Completing PRO measures as part of SCFU seemed to: 
• Increase the patients’ focus on their health in 
new ways and 
• Facilitate tracking symptoms before they 
became too serious. 
For a minority of the patients, the PRO measures: 
• Were irrelevant to their situation and 
• Made it difficult to get the message across. 
Nurse consultation 
 
Introducing nurses into follow-up seemed to elicit: 
• An experience of being able to set the agenda 
and a feeling of being heard and taken care of,  
• A sense of more time, and 
• A space where patients would talk to the nurse 
about issues that they would not necessarily 
discuss with a physician. 
A minority of the patients stated that the switch in 
profession:  
• Made no difference. 
Using the telephone 
 
Introducing telephone consultations seemed to 
• Elicit discussions of a more sensitive nature 
than face-to-face meetings and  
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In summary, for most patients, a shared care follow-up program seemed to 
contribute to easing their everyday lives in terms of alleviating practical, disease-
related, and emotional concerns connected with hospital visits, whereas for others, 
the initiative led to no significant changes in their lives. Patient accounts suggest that 
their feeling of security was not compromised by participating in the shared care 
follow-up initative, but the possibility of extra consultations was important to the 
patients. As a part of intitiative , the patients were asked to complete a PRO 
measures and it seemed that introducing PRO measures into follow-up contributed 
to increased self-monitoring of health status. However, some patients found the PRO 
measures to be irrelevant, which led to frustration. Another new element introduced 
in the shared care follow-up program was the nurse-led telephone consultation. 
Based on patient accounts, introducing nurses into follow-up seemed to facilitate an 
open dialogue and a shift from disease-related topics to topics of a more 
psychosocial nature. Furthermore, patients seemed more ready to discuss topics 
that they normally would not bring up with a physician. The patient narratives 
suggested that telephone consultation provided an undisturbed room for dialogue, 
where concerns of all kinds could be addressed (134).  
 
5.3. STUDY III 
Aim: to identify patients who experienced deterioration in HRQL after relapse 
treatment and to investigate HRQL patterns in a cohort of hematological cancer 
patients with relapse or progressive disease. 
 
Results (135): In total, 178 patients were eligible for the study. Of the 178 eligible 
patients, 104/178 (58%) were sent baseline PRO measures. Reasons for ineligibility 
and number of non-responses at baseline are illustrated in Figure 4. Patient 
characteristics are presented in Table 6. (135). A response rate to baseline of 14/104 









PATIENT-REPORTED OUTCOMES ON THE TRAJECTORY OF HEMATOLOGICAL CANCER 
48 
Figure 4: Flowchart illustrating the inclusion process and number of non-responses to baseline and loss to 
follow-up at each timepoint (135) 
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Table 6: Clinical and sociodemographic characteristics of patients with hematological cancer experiencing 
relapse (135) 
 
¶Aggressive lymphomas include: Diffuse large B-cell lymphoma, Hodgkin lymphoma, Non-Hodgkin 
lymphoma, T-cell large granular lymphocytic leukemia, Angioimmunoblastic T-cell lymphoma. ǂChronic 
leukemia include: Chronic lymphocytic leukemia, Small lymphocytic leukemia, Chronic myeloid leukemia, 
Hairy cell leukemia. §Indolent lymphomas include: Follicular lymphoma, Maltoma, Mantle cell 
lymphoma, Nodal marginal zone lymphoma, Lymphoplasmacytic lymphoma, Waldenström’s 
macroglubulinemia, Splenic marginal zone lymphoma, Peripheral T-Cell lymphoma ¥ Acute leukemia 
include: Acute myeloid leukemia, Acute lymphoid leukemia, Myelodysplastic syndrome. 
 
At baseline,  the patients reported moderate and severe symptoms and functional 
problems in all HRQoL domains. The three most affected HRQoL domains were 
insomnia (moderate: 26 (29%); severe: 19 (21%); global health status (moderate: 41 
(46%); severe: 19 (21%), and fatigue (moderate; 40 (44%); severe: 20 (22%)) (135). 
Furthermore, the patients reported both improvements and deterioration at the 12-
month follow-up, with 16%–18% experiencing deterioration in fatigue, insomnia, 
diarrhea, and/or appetite loss as well as decreased role, emotional, and/or cognitive 
functioning (135). Rates of improvement and deterioration in HRQoL for the total 












n (%)=90 (100) 
Sex    
Male 50 (70.4) 10 (52.6) 60 (66.7) 
Female 21 (29.6) 9 (47.4) 30 (33.3) 
Median age, years 
(range) 
70.0 (34–93) 66.0 (44–88) 69.5 (34–93) 
Age    
<50 1 (1.4) 2 (10.5) 3 (3.3) 
50–59 8 (11.3) 3 (15.8) 11 (12.2) 
60–69 23 (32.4) 8 (42.1) 31 (34.4) 
>70 39 (46.5) 6 (31.6) 45 (43.3) 
Diagnosis    
Aggressive 
lymphoma 
11 (15.5) 13 (68.4) 24 (26.7) 
Indolent lymphoma 22 (31.0) 2 (10.5) 24 (26.7) 
Chronic leukemia 18 (25.4) 0 (0.0) 18 (20.0) 
Acute leukemia 5 (7.0) 4 (21.1) 9 (10.0) 
Multiple myeloma 15 (21.1) 0 (0.0) 15 (16.7) 
Number of relapses    
1 38 (53.5) 17 (89.5) 55 (61.1) 
2 16 (22.5) 2 (10.5) 18 (20.0) 
≥3 15 (21.1) 0 (0.0) 15 (16.7) 
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Table 7: Improvement or deterioration in health-related quality of life, anxiety, or depression from 
baseline to the 12-month follow-up for the total cohort (135) 




Deterioration, n (%) Improvement, n (%) 
EORTC-QLQ-C30   
Global health status 7 (14) 13 (27) 
Physical functioning 5 (10)  8 (16)  
Role functioning 8 (16)  14 (28)  
Emotional functioning 8 (16)  8 (16) 
Cognitive functioning 8 (16)  6 (12)  
Social functioning 3 (6)  11 (22)  
Fatigue 9 (18)  13 (26) 
Nausea and vomiting 2 (4)  4 (8)  
Pain 4 (8)  11 (22) 
Dyspnea 5 (10)  7 (14) 
Insomnia 9 (18)  12 (24)  
Appetite loss 8 (16)  15 (30)  
Constipation 6 (12)  5 (10)  
Diarrhea 9 (18)  8 (16)  
Financial difficulties 3 (6)  4 (8)  
HADS   
Anxiety 5 (11)  1 (2)  
Depression 1 (2)  1 (2)  
N; number of patients, EORTC QLQ-C30; the European Organization for Research and Treatment of 
Cancer, HADS; the Hospital Anxiety and Depression Scale 
 
When attempting to identify patient characteristics associated with deterioration in 
HRQoL at 12-months, a statistically significant correlation between impaired role 
functioning and estimated survival ≤2 years was found (OR 0.14, CI: 0.02; 0.95, 
p=0.04) (135).  
Finally, clinically relevant changes from baseline to the 12-months follow-up were 
found in the CIT group for insomnia (medium improvement, p=0.001) and in the total 
cohort for global health status (small improvement, p=0.03) and nausea and 
vomiting (small improvement, p=0.03) (135).  
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CHAPTER 6. DISCUSSION 
The overall aim of this PhD thesis was to examine the potential of PROs in patients 
with hematological cancer throughout the disease trajectory and to determine if 
PROs could help facilitate PCC and contribute to increased quality of care in these 
patients. Three studies were conducted to address the overall aim. The key results, 
findings, and methodological considerations are discussed below.  
6.1. DISCUSSION OF RESULTS AND FINDINGS 
In line with the multiple-method research design (Fig. 2), results from all three 
studies will be discussed in the context of the overall aim, each other, and existing 
research. The potential value of PROs in patients with hematological cancer will be 
discussed as well as strengths, limitations and challenges identified during the three 
studies to be considered when applying PROs in clinical practice.  
6.1.1. PATIENT ACCEPTABILITY OF COMPLETING PROS 
Overall, the results of Study I and Study II demonstrated that the initiative seemed 
feasible and that patient experience was mainly positive (133,134). The results of the 
patient acceptability survey in Study I demonstrated that most patients found it easy 
to understand the questions and found that it made sense to complete the PRO 
measures. These results are supported by the findings in Study II, in which most 
patients had positive experiences with completing the PRO measures. However, 
results of both studies also suggest that some patients found the PRO measures to 
be irrelevant to their situation, and in some cases, completing the PRO measures 
caused frustration because patients found it difficult to get their message across 
(133,134). This outcome indicates a need for careful consideration of the 
characteristics of the patient population when selecting or developing PRO measures 
to ensure that they are relevant and understandable to the selected patients. In fact, 
patients do have preferences about the content of PRO measures (114). In a 
randomized controlled trial comparing three PRO measures, researchers found that 
redundant questions and questions for which responses were unlikely to change 
over a short period of time were a nuisance to the patients. Furthermore, the 
patients emphasized that clear response options were important (114). These results 
are supported by the findings of Snyder et al. (2007) who investigated the 
importance of the content in selected PRO measures as rated by patients and 
clinicians (165). These authors found that patients pointed out questions related to 
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information about treatment and care coordination as important issues they need 
addressed. Interestingly, the clinicians considered questions related to pain and 
symptoms to be most important to patients, hence indicating divergent views on the 
most essential concerns to be addressed in the clinical practice (165). Also,  Noonan 
et al. (2017) reported on factors that are important to consider when implementing 
PRO in clinical practice and pointed out that patient factors in terms of 
socioeconomic characteristics and perceived meaningfulness of PRO are essential 
elements to consider (166) supporting the fact that varying relevance of questions 
has been established as a barrier to the use of PROs in clinical practice (167). These 
findings support the argument that the patient perspective should be considered 
when developing PRO-based interventions. Thus, given the results from studies I and 
II and supported by existing research, patient interviews should be considered as a 
part of the process when choosing existing PRO measures for PRO interventions. 
Such interviews may guide the selection of PRO measures because an a priori 
qualitative inquiry into patient preferences and needs may assist in determining the 
topics and questions that the specific patient population finds important (166). 
 
6.1.2. PROS AS A TOOL FOR SELF-REFLECTION ON HEALTH 
PROs used in clinical practice can be valuable in terms of tracking changes in health 
status over time as well as generating increased self-focus on health status (117). 
Greenhalgh et al. (2018) found that as a result of completing PROs in clinical practice, 
patients would reflect on their health situation (117). These results are consistent 
with those of Study I, in which most patients reported that completing the PRO 
measures made it easier for them to recall symptoms and adverse events (133). 
Furthermore, their accounts in Study II indicate that patients used the PRO measures 
to track changes over time as well as using them as a screening tool for reflecting on 
their current health situation (134).  
The patients’ narratives in Study II suggested a shift in focus from disease-related to 
a more comprehensive approach to follow-up, highlighting that they would bring up 
concerns during nurse-led telephone consultations that they would not necessarily 
have raised during a physician consultation (134). These findings are in line with 
those of Greenhalgh et al., who reported that patients would raise emotional and 
HRQoL issues with their physicians but that the physicians viewed such factors as 
outside of their scope (117). Moreover, Pennery et al. (2000) found that many 
survivors of breast cancer felt uneasy raising questions especially of an emotional 
nature during consultations and that the majority of the patients would prefer breast 
cancer nurses to provide cancer survivorship care (168). Combined, these findings 
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are suggestive of the need for a multi-disciplinary approach to care for the whole 
patient in terms of addressing each patient’s individual needs for support. 
 
To date, studies have found that using PROs in clinical practice as a basis for 
consultations positively affects the care process in terms of patient satisfaction and 
as a tool for dialogue (90,117,169); however, little evidence exists on the impact of 
PROS on patient outcomes (170). In a systematic review of the evidence, researchers 
found PROs to be valuable as a screening and management tool but found little 
evidence that PROs improved patient outcomes (170). In the current work, results of 
studies I and II indicate that PROs seem to support the immediate care process in 
terms of better communication and detection of health problems (133,134). Further 
high-quality research on how PROs affect patient outcomes is still warranted. 
 
6.1.3. PROS AS A TOOL OF IDENTIFYING HEALTH PROBLEMS 
Study III was an investigation into HRQoL patterns in patients with relapsed or 
progressive hematological disease with the aim to identify those who experienced 
deterioration in HRQoL domains over time (135). Study III demonstrated that the 
patients reported moderate and severe symptoms and functional problems at 
baseline and that some patients experienced deterioration at 12 months of follow-
up. The fact that these patients experience deterioration in HRQoL domains in the 
course of relapse treatment is a clear indication of a need for intervention. Research 
has shown that PROs are valuable in terms of monitoring HRQoL and adverse events 
during cancer treatment (121). Basch et al. (2016) found that regular monitoring of 
symptoms in a cohort of patients with advanced solid tumors receiving 
chemotherapy improved HRQoL compared to the non-intervention group (121). 
Furthermore, the intervention group was less likely to be admitted to the hospital 
and tolerated treatment longer than patients not completing PRO measures. Finally, 
the authors found that regular symptom monitoring was associated with an increase 
in overall survival compared to the non-intervention group (121,171). This study was 
conducted in a group of patients with metastatic cancer, which suggests that 
symptom monitoring during relapse treatment in patients with relapsed or 
progressive hematological cancer may well be assumed to yield similar positive 
outcomes. Although based on a small number of patients, Study III highlights the 
complexity of relapse, as we could not identify obvious factors that might indicate 
patients who would experience a deterioration in HRQoL during relapse treatment 
(135). However, by introducing PRO, we established that some patients did 
experience a deterioration in HRQoL during the year after relapse diagnosis. This 
PATIENT-REPORTED OUTCOMES ON THE TRAJECTORY OF HEMATOLOGICAL CANCER 
54 
result suggests that routine PRO assessments during relapse treatment may play a 
role in decision making in terms of initiating earlier symptom management and 
supportive care interventions.  
 
Routine collection of PROs has proven successful in improving communication 
between health professionals and patients (117,172), a benefit that Study I also 
established (133). The findings of Study II add to the evidence, with patient accounts 
suggesting that the informality of the nurse consultations motivated them to raise 
health concerns that they might not necessarily have brought up during a 
consultation with a physician (134), thus indicating improved communication. 
Efficient communication between health professionals and patients is an essential 
component of shared decision making and using PROs may allow patients to engage 
in decision making based on their account of HRQoL and symptoms, hence 
facilitating targeted and individualized patient care (166,173). 
 
6.1.4. DOES “ONE-SIZE-FIT-ALL”? 
Based on the results from all three studies, it is clear that using PROs in hematological 
cancer survivorship offers potential in terms of increased self-reflection on health, 
patient involvement, and identifying health problems (133–135). However, looking 
at the divergent positions among the patients in Study I and Study II in terms of 
perceived value and relevance of completing PROs, it is clear that a “one-size-fits-all” 
approach, understood as a fixed cancer survivorship care model applied to all 
patients, may not support every individual patient’s needs. Personal resources, 
preferences, and stage on the hematological disease trajectory should be considered 
when assigning patients to follow-up (166). One way of addressing this issue could 
be to introduce routine assessment of individual needs and preferences before the 
patient enters survivorship care. A thorough assessment of patient preferences in 
terms of mode of follow-up and needs in terms of assistance would build a solid basis 
for patient-centered survivorship care (174). 
Study I demonstrated the feasibility of a shared care follow-up initiative based on 
nurse-led telephone consultations and completion of PROs, which suggests that 
PRO-based follow-up may have potential for patients with hematological disease 
(133). PRO-based follow-up was introduced in Denmark by Ambuflex, which 
developed online platforms for several chronic diseases as well as breast, lung, and 
prostate cancers (132). The aim of Ambuflex is to use PRO for “clinical decision 
support to improve quality of care, promote patient-centered care, optimize the use 
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of resources in the healthcare system and use data for research purpose” (132). The 
Ambuflex solution uses algorithm-based decision making in terms of assessing a 
patient’s need for hospital contact, and low HRQoL scores indicate no need for 
hospital contact. The implementation of the solution has led to a decrease in 
scheduled visits in busy outpatient clinics (132), a tendency that the results of Study 
I also suggested (133). Moreover, the findings from Study II indicate that fewer visits 
to the outpatient clinic contributed to various positive elements, such as 
convenience and fewer encounters with other patients with cancer (134). 
Acknowledging the value of fewer or even no visits have for most patients and for 
the healthcare system, it is, however, important to consider if this type of follow-up 
would benefit all patients.  
The findings from Study II suggest that although the patients appreciated the 
convenience of fewer visits, some of them seemed to need physical visits and 
examination despite having no symptoms or other health-related problems (134). It 
is well-established that survivors of hematological cancer report unmet needs in 
terms of fear of recurrence and finding the transition into survivorship difficult 
(21,22). These needs raise the question of whether they would be addressed if 
cancer survivorship care was based solely on PROs without consultation with a 
health professional.  
This PhD thesis indicates that PROs may have potential in survivors of hematological 
cancer in terms of creating self-focus on their health situation and detecting health 
problems. However, it also indicates that PROs may not work on their own in all cases 
but need support from health professionals and, in this situation, nurses. 
Brandenberg et al. (2017) explored cancer survivors needs for support during 
survivorship and found that they had a deep need for screening, possibly as a result 
of fear of recurrence (175). Furthermore, the authors found that the patients needed 
emotional support, in keeping with Marbach et al. (2011), who also found emotional 
support to be essential to cancer survivors (176). Thus, cancer survivors report 
supportive care needs that may not be addressed by substituting consultations with 
PRO assessments and that health professionals should address. 
 
6.1.5. PATIENT-REPORTED OUTCOMES AND PATIENT-
CENTERED CARE 
Research has established that applying PROs in clinical practice may assist in 
providing PCC as a result of patient involvement and enhanced communication 
(117,166). Based on the findings of all three studies (133–135), PROs may have 
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potential in terms of improving the process of care in patients with hematological 
cancer, assisting in facilitating PCC within this patient group. PCC is defined as: “a 
partnership among practitioners, patients, and their families (when appropriate) to 
ensure that decisions respect patient’s wants, needs, and preferences and that 
patients have the education and support they need to make decisions and participate 
in their own care” (125,128). Based on the findings of Jayadevappa and Chhatre 
(2011) and Hobbs (2009), this definition implies that delivery of high-quality care is 
based on the development of a relationship between the health professional / nurse 
and the patient, as well as on information pratices to ensure that each patient is 
cared for based on their specific needs and preferences (127,177). Thus, a central 
element in the provision of PCC is to ensure that healthcare is based on a patient’s 
individual needs.  
 
In recent years, nurse researchers, clinicians, leaders, and educators have developed 
the Fundamentals of Care framework (FoC) with the aim of addressing challenges 
within the nursing profession in the pursuit of person-centered and situation-
oriented nursing care (178). Kitson et al. (2013) proposed that the nursing profession 
has lost sight of the fundamental needs of the patients as focus has shifted to a more 
task-driven provision of nursing care (179). Hence, FoC focuses on directing 
healthcare and nursing in particular toward patient needs and “how nursing can put 
the fundamentals of care at the center of its activity” (178), emphasizing the demand 
for PCC. The core element of FoC is the relationship between the patient and the 
nurse – a relationship that enables both to “confidently and competently assess, 
plan, implement and evaluate care around the fundamental care needs” (178). This 
relationship should be based on respect, trust, and mutual goals for the patient’s 
care (178). FoC accentuates that the nurse should take a holistic approach to patient 
care, focusing on the patient as a whole and not solely on the disease or treatment. 
By viewing the results and findings from Study I and Study II within the framework 
of FoC, it can be argued that introducing nurse consultations based on PROs gets to 
the core of FoC because the relationship between the patient and the consulting 
nurse was described as creating a personal space for dialogue where sensitive issues 
could be discussed (133,134). Moreover, some patients also stated that they talked 
not about the disease but about the patient as a person, suggesting a trusting 
relationship, which according to FoC is essential to providing PCC (134,178,179). 
 
FoC also encompasses action plans for further integration and implementation of 
FoC and PCC. One of these actions is application or development of assessment tools 
that tap into physical, psycho-social, and relational needs of the patients (178). This 
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demand is in line with the purpose and possibilities that lie within the concept of 
collecting PROs in clinical practice (180). 
Study I and Study II indicate that when patients complete PROs prior to 
consultations, emerging health problems and needs for interventions are identified 
and addressed (133,134). Moreover, most patients found value in completing PROs, 
as they themselves became more observant of potential changes in their health 
situation. Based on these results and findings, FoC may be applied to the care of 
patients with hematological cancer by implementing PROs in clinical practice, thus 
eliciting information on physical and psycho-social needs to be addressed in the 
patient encounter. 
Another action needed according to the FoC working group is the development of 
tools to measure patient experience and quality of care. This emphasis supports the 
previously noted need to involve patients in the development and implementation 
of PRO interventions in clinical practice with the aim of facilitating PCC. 
 
6.2. METHODOLOGICAL CONSIDERATIONS 
Below, the multi-method research design is discussed, followed by a discussion of 
the methodological considerations related to studies I, II, and III, including their 
strengths and limitations.   
6.2.1. MULTI-METHOD RESEARCH DESIGN 
This PhD thesis was designed as a multi-method study encompassing both 
quantitative and qualitative research methods (136). This method has allowed for a 
quantitative understanding of the feasibility of the intervention as well as a deeper 
understanding of how patients experienced the shared care follow-up and the 
impact it had on their lives.  
Study I and Study II were designed to complement each other in terms of collecting 
data on the value of the intervention and PRO (133,134). Data from the two studies 
were collected and analyzed individually and then merged into a joint discussion, 
enabling a deeper understanding of the potential of the intervention. The multi-
method research design has proven successful in this context because the results 
from Study I were informed and strengthened by the patient narratives in Study II, 
which confirmed the results of Study I. Also, Study II added the patient perspective 
on nurse-led telephone consultations and PROs in hematology to the literature, 
which to date has been limited. Although, a multi-method research approach allows 
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for a broader and deeper understanding of a subject it may also be assumed that 
breadth of knowledge about a topic may take precedence over depth as applying 
both methods may be extra time consuming (137). Thus, if the research design had 
been solely quantitative, it may have been possible to assess the feasibility of Study 
I based on stronger and additional estimates. However, a drawback of this argument 
is that such an approach would have eliminated the possibility of adding the patient 
perspective, which is vital to provision of PCC.  
 
Study III was not a completely integrated part of the multi-method research design 
because the included patient population diverged from that in Study I and Study II. 
The patient population in Study III was pre-specified because it was a sub-study of 
an ongoing project (ProGen/ProSeq) within the Department of Hematology. This 
difference has made it more challenging to provide a joint discussion with Study I 
and Study II. However, the results of Study III offer an answer to the overall aim, and 
the three studies converged on similar results and findings. Thus, despite the 
different patient populations, the three studies have all provided answers to the 
question of the potential role for PROs in the provision of PCC during the 
hematological disease trajectory. 
 
6.2.2. STUDY I 
Study I was designed with the aim of testing the feasibility of the shared care follow-
up initiative (133). This study did not include a control group, which limited any 
conclusions about whether the shared care follow-up initiative increased quality of 
care compared to standard follow-up. However, this study adds to the existing 
literature by demonstrating the feasibility of nurse-led telephone consultations in a 
hematological setting in terms of a high level of patient adherence and low rate of 
exclusions and extra in-hospital contacts. 
During the study period, we included 80/83 patients based on the physician 
assessment at a scheduled visit. At present, we cannot provide further information 
regarding the recruitment process in terms of characteristics of patients who were 
offered participation but declined. In hindsight, the recruitment process could have 
been conducted more systematically, resulting in a more transparent process. Data 
in terms of clinical, socioeconomics characteristics and reasons for declining 
invitation to participate would have been useful for determining any specific and 
systematic characteristics in patients declining participation (181,182). This 
information is important for assessing potential selection bias, which may have 
influenced the interpretation of the results. A biased population would in this 
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context mean a more favorable outcome, overestimating the feasibility of the 
intervention. However, only three patients declined participation indicating that this 
issue may not have contributed considerably to potential overestimation of the 
feasibility of the intervention. 
 
This feasibility study was designed using international validated and disease-specific 
PRO measures. EORTC-QLQ-30 and HADS have been used extensively within the PRO 
literature and as the basis for PRO-based follow-up developed by Ambuflex 
(132,139,141). In a study investigating the feasibility of Ambuflex, the authors found 
the interventions to be feasible in terms of high response rates and high satisfaction 
(132), underlining the value of these PRO measures as part of PRO-based follow-up 
in clinical practice. However, the results and findings from Study I and Study II also 
suggest that some patients found the PRO measures to be irrelevant and 
burdensome (133,134). A patient inquiry into the relevance of the PRO measures is 
vital for further development of the shared care follow-up initiative and prior to 
implementation. 
 
6.2.3. STUDY II 
In study II, 12 patients were interviewed, all of whom met the selected inclusion 
criteria in terms of variation in age, sex, diagnoses, and time since primary treatment 
(134). Although this study presents accounts based on variation within the patient 
population, it can be argued that because of this small number of patients, the 
findings offer only a limited narrative within the research context. However, 
generalizability in qualitative research is often not the goal as researchers generally 
seek to generate a deep and context-specific understanding of a given situation 
(137). Schofield (1993) argues that: “The goal [of qualitative research] is not to 
produce a standardized set of results that any other careful researcher in the same 
situation or studying the same issues would have produced. Rather it is to produce a 
coherent and illuminating description of and perspective on a situation that is based 
on or consistent with detailed study of that situation” (183). Thus, the findings of this 
study is based on narratives of patients with hematological cancer who had 
experience from the shared care follow-up initiative offering a deep exploration of 
the given situation and as such is assumed to provide a credible answer to the 
proposed study aim.  
 
Data saturation is an ongoing debate within qualitative research because researchers 
often claim that saturation has been achieved without being able to prove it (184). 
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In Study II, the decision about saturated data was made at the timepoint at which no 
new information was elicited from the patient narratives. However, this rationale for 
data saturation has been criticized because it offers little information about the 
underlying assessment on which the decision is based (185). To forestall such 
unjustified decisions, Malterud et al. (2016) have proposed “information power” as 
a concept to guide choices about sample size in qualitative studies (185): 
“Information power indicates that the more information the sample holds, relevant 
for the study, the lower amount of participants is needed” (185). This concept holds 
that the narrower the research question and the denser the sample specificity, the 
smaller the sample size that will be needed. The aim of Study II was to elicit the 
experiences of patients with hematological cancer participating in a shared care 
follow-up initiative, resulting in a group of patients who had highly specific 
knowledge about this subject. This argument supports the need for a relatively small 
sample size in Study II, justifying the timepoint chosen for data saturation. 
 
6.2.4. STUDY III 
In Study III, 104 patients with relapsed or progressive hematological disease were 
included, of whom 90 responded to the baseline PRO measures (135). During the 
study period, 40 patients dropped out, for a dropout rate of 44%. Non-response to 
PRO measures during longitudinal studies is known to lead to unintended bias as well 
as loss of study power (186), and the dropout rate has undoubtedly reduced 
statistical power and decreased the rigor of the study results. However, despite low 
rigor, this study adds important information to a limited knowledge base about 
HRQoL in patients with relapsed or progressive hematological disease.  
The timepoints for collection of PRO data were set to baseline and 3, 6, 9, and 12 
months. It could be argued that the intervals were too widespread for a cohort of 
patients with advanced disease. The intervals were chosen because the goal was to 
investigate an overall HRQoL pattern over time. However, by shortening the intervals 
between PRO assessments, it is likely that we could have presented more robust 
results in terms of, e.g., a lower dropout rate because of death. 
The study population consisted of patients with a wide variety of hematological 
cancer diagnoses, resulting in a heterogeneous sample. This heterogeneity posed a 
challenge for grouping the patients for analysis purposes. We chose to group the 
patients based on treatment strategy – CIT and non-CIT. We opted for this decision 
because we initially intended to investigate the level of depression and anxiety based 
on a clinical assumption that patients receiving palliative care would be more 
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depressed and anxious than patients receiving CIT. However, the results showed that 
neither group reported any symptoms of either depression or anxiety. In hindsight, 
to address the current aim of the study, we could have grouped the patients based 
on estimated survival over/under 2 years after relapse diagnosis because it could be 
argued that prognosis in terms of survival rather than treatment strategy affects 
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CHAPTER 7. CONCLUSION 
This PhD thesis provides new knowledge about the use of PROs as they relate to the 
trajectory of hematological cancer in the context of PCC and quality of care.  
The use of PROs as part of a shared care follow-up initiative in a cohort of patients 
with B-cell disease in remission and low risk of relapse is feasible, as demonstrated 
by high patient adherence and a high level of acceptability of completing PROs as 
part of the follow-up. 
A qualitative exploration of patient experiences suggests that completing PROs as 
part of follow-up is valuable to most patients in terms of tracking changes in their 
health situation and generating increased self-reflection about their health. 
Moreover, the patients experienced a shift from a disease-related to a more holistic 
focus, which seemed to improve communication in terms of engaging in discussions 
not normally had with the physicians. 
Longitudinal HRQoL assessments in a cohort of hematological patients with relapse 
or progressive disease show that this patient population report moderate and severe 
symptoms and functional problems at baseline and that some patients experience 
deterioration of HRQoL during the first year after relapse diagnosis. Hence, routine 
symptom monitoring may be valuable to detect and manage symptoms and 
supportive care needs during treatment for relapsed or progressive disease. 
Overall, this multi-method PhD thesis demonstrates that PROs are valuable during 
the trajectory of hematological cancer in terms of increased patient involvement, 
identifying health problems, and improving patient–provider communication and as 
a supporting role in shared decision making. Although divergent patient experiences 
suggest that a one-size-fits-all approach is undesirable, PROs seem to provide health 
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CHAPTER 8. IMPLICATIONS FOR CLINICAL 
PRACTICE AND FUTURE RESEARCH 
Based on the results, discussion, and conclusion of this PhD thesis, the following 
section briefly elaborates on the possible implications of this research for clinical 
practice and provides a direction for future research. 
 
8.1. IMPLICATIONS FOR CLINICAL PRACTICE 
Cancer survivorship care of patients with hematological disease in remission, based 
on nurse-led telephone consultations and pre-collected PROs, may have the 
potential to target and individualize consultations that address each individual 
patient’s needs. Implementing PROs in hematological cancer survivorship care may 
provide positive benefits in terms of increased patient involvement, identification of 
health problems, and better provider–patient communication and support shared 
decision making. Moreover, a multi-disciplinary approach to cancer survivorship may 
allow for a more holistic approach to a patient’s supportive care needs and for 
patients to raise different concerns with the health professionals with whom they 
are most comfortable in a given situation. Finally, it may be desirable to implement 
needs assessments prior to entering survivorship care to assess a patient’s 
preferences and need for support. 
Patients with hematological cancer with relapsed or progressive disease report 
moderate and severe symptoms and functional problems. In addition, some patients 
experience a deterioration in HRQoL during the first year of relapse treatment. These 
findings suggest the need to focus on symptom assessment and monitoring during 
treatment to manage individual patient symptom relief and address functional 
problems to further stabilize or improve HRQoL. Implementation of PROs in 
hematological clinical practice offers the opportunity to address symptoms earlier 
and support patients in maintaining usual activities. This support could be provided 
by multidisciplinary initiatives aimed at facilitating maintenance and, better yet, 
improvement of HRQoL.  
Finally, the routine use of PROs may contribute to provision of PCC within the FoC 
framework by focusing nursing care on each patient’s individual needs. 
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8.2. FUTURE RESEARCH 
The patient perspective and assessment of patient needs and preferences are 
essential when developing and implementing PRO-based interventions aimed at 
providing PCC. Therefore, development and implementation of future PRO-based 
interventions should be preceded by qualitative research studies exploring patient 
needs and preferences for the intervention in question, ensuring a solid foundation 
for future PRO-based interventions. 
This research established a variable patient experience of the relevance of the 
applied PRO measures, which caused frustration for some. This finding points to the 
need to target chosen PRO measures even more; PRO measures for PRO-based 
interventions should be validated with the patient population in question by 
qualitative interview prior to study start or implementation. 
Solid research on HRQoL in patients with hematological cancer with relapsed or 
progressive disease is limited. The research presented in this thesis provides some 
answers but is limited because of small numbers of patients and the disease 
heterogeneity in this population. Future HRQoL research within this patient 
population is needed. Of note, to collect solid data and provide robust results, future 
HRQoL research within this patient population should be designed with the 
consideration of a relatively large dropout rate because of death.  
The results of this research indicated a large symptom burden as well as 
deterioration in HRQoL among these patients. To address symptoms and supportive 
care needs during treatment for relapsed or progressive disease, further research 
should encompass symptom monitoring based on PROs during treatment of these 
patients to identify potential positive patient outcomes.  
This PhD thesis demonstrates that PROs may offer positive potential during the 
hematological disease trajectory in terms of increased patient involvement and 
provider–patient communication. However, the literature offers little evidence of 
positive patient outcomes as a result of applying PROs in clinical practice. Future 
research should direct attention towards  this area to allow assessment of the full 
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Myeloproliferative Neoplasm – Symptom Assessment Form (MPN-SAF) (140). 
Instruktioner: Besvar venligst alle spørgsmål så godt som muligt. Symptomerne 
gælder den seneste uge, hvis intet andet er nævnt. 
   
Symptom  Graduer fra 1 til 10, hvor 1 er mindste 
symptom og 10 er værste tænkelige. (0 er 
ingen symptomer overhovedet)  
Sæt ring om det tal, der bedst beskriver din træthed 
netop nu  
0 (ingen træthed) 1 2 3 4 5 6 7 8 9 10 (værst 
tænkelige)  
Sæt ring om det tal, der bedst beskriver din 
gennemsnitlige træthed det seneste døgn  
0 (ingen træthed) 1 2 3 4 5 6 7 8 9 10 (værst 
tænkelige  
Sæt ring om det tal, der bedst beskriver den værste 
træthed du har følt det seneste døgn  
0 (ingen træthed) 1 2 3 4 5 6 7 8 9 10 (værst 
tænkelige  
 
Sæt ring om det tal, der bedst beskriver hvordan træthed (udmattelse) igennem det seneste døgn har 
indvirket på: 
Dine daglige aktiviteter 0 (slet ikke) 1 2 3 4 5 6 7 8 9 10 (fuldstændigt)  
Dit humør  0 (slet ikke) 1 2 3 4 5 6 7 8 9 10 (fuldstændigt)  
Din bevægelsesfrihed/evne til at bevæge dig 
omkring  
0 (slet ikke) 2 3 4 5 6 7 8 9 10 (fuldstændigt)  
Dit arbejde såvel som dine daglige gøremål 0 (slet ikke) 1 2 3 4 5 6 7 8 9 10 (fuldstændigt)  
Din omgang med andre mennesker  0 (slet ikke) 1 2 3 4 5 6 7 8 9 10 (fuldstændigt)  
Din livsglæde  0 (slet ikke) 1 2 3 4 5 6 7 8 9 10 (fuldstændigt)  
 




Tidligt forekommende mæthedsfølelse ved 
måltider  
0 (ingen) 1 2 3 4 5 6 7 8 9 10 (værst tænkelige)  
Smerter i maven / bughulen  0 (ingen) 1 2 3 4 5 6 7 8 9 10 (værst tænkelige)  
Ubehag i maven / bughulen  0 (ingen) 1 2 3 4 5 6 7 8 9 10 (værst tænkelige)  
Inaktivitet  0 (ingen) 1 2 3 4 5 6 7 8 9 10 (værst tænkelige)  
Problemer med hovedpine 0 (ingen) 1 2 3 4 5 6 7 8 9 10 (værst tænkelige)  
Problemer med koncentrationen – sammenlignet 
med før min sygdom 
0 (ingen) 1 2 3 4 5 6 7 8 9 10 (værst tænkelige)  
Svimmelhed 0 (ingen) 1 2 3 4 5 6 7 8 9 10 (værst tænkelige)  
Prikken/stikken/følelsesløshed/ i hænder og fødder 0 (ingen) 1 2 3 4 5 6 7 8 9 10 (værst tænkelige)  
Søvnproblemer 0 (ingen) 1 2 3 4 5 6 7 8 9 10 (værst tænkelige)  
Nedtrykthed eller været ked af det 0 (ingen) 1 2 3 4 5 6 7 8 9 10 (værst tænkelige)  
Seksuelle problemer (nedsat lyst eller dysfunktion) 0 (ingen) 1 2 3 4 5 6 7 8 9 10 (værst tænkelige)  
Hoste  0 (ingen) 1 2 3 4 5 6 7 8 9 10 (værst tænkelige)  
Nattesved  0 (ingen) 1 2 3 4 5 6 7 8 9 10 (værst tænkelige)  
Kløe  0 (ingen) 1 2 3 4 5 6 7 8 9 10 (værst tænkelige)  
Knoglesmerter (diffus smerte, ikke ledsmerter)  0 (ingen) 1 2 3 4 5 6 7 8 9 10 (værst tænkelige)  
Feber (over 37.8) 0 (aldrig) 1 2 3 4 5 6 7 8 9 10 (dagligt)  
Utilsigtet vægttab de seneste 6 mdr. (dvs. ikke 
vægttab som resultat af træning eller slankekur)  
0 (intet) 1 2 3 4 5 6 7 8 9 10 (værst tænkelige) 
Hvad vejer du i dag? (Kg)  
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Interview guide developed for Study II (134). 
Tema Spørgsmål Supplerende spørgsmål 
Dine oplevelser • Prøv at fortælle, med 
dine egne ord, hvordan 
du overordnet oplevede 
at deltage i projektet. 
 




• Oplevede du at du 
kunne bruge 
spørgeskemaerne til 
noget forud for samtale? 
• Var der noget, du oplevede 
som særligt godt? 
• Var der noget, du oplevede 
som knap så godt? 
• Var der noget du undrede dig 
over? 
• Hvordan passede antallet af 
spørgsmål? Var der for mange 
/ for få?  
• Var spørgsmålene relevante? 
• Var der noget du savnede? 
• Hvordan var det at sætte tal 
på symptomer? 
• Gav de anledning til 
forberedelse? 
• Hvilken betydning havde det 
for dig? 
• Hvordan oplevede du, at dine 
svar blev brugt i 
opfølgningen? 
Ændret praksis • Hvordan var overgangen 
mellem at blive fulgt 
udelukkende af en læge 
i ambulatoriet til at 
skulle følges hver anden 
gang af en sygeplejerske 
over telefonen? 
 
• Hvilken betydning har 
det haft, at det var en 
sygeplejerske, du talte 
med? 
 
• Var der noget, du manglede 
ved telefonkonsultationen? 
• Følte du behov for at se en 
læge efter 
sygeplejerskekonsultationen? 
• Hvilken betydning har det 
haft for dig, at samtalen med 
sygeplejersken foregik over 
telefonen? 
• Kan du fortælle lidt omkring 
forskellene mellem at tale 
med en læge og en 
sygeplejerske, hvis der var 
nogen? 
• Hvis ja, hvordan kom det til 
udtryk? 
• Hvis ja, hvilken betydning har 
det ændrede fokus haft for 
dig? 
Behov for støtte til 
patientens aktuelle tilstand 
• Hvad har især fyldt for 
dig i dit forløb? Er der 
noget der har været 
specielt svært for dig? 
 
• Hvordan oplevede du at 
lægen/sygeplejersken gik op 
i, hvad der var vigtigt for dig? 
• Hvordan oplevede du at 
læge/sygeplejersken støttede 
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• I forhold til hvad der har 
fyldt for dig, hvordan 
oplevede du at få den 
støtte, du havde brug 
for? 
dig i, hvad der var vigtigt for 
dig? 
• Var der problemstillinger, der 
var nemmere at tale om / få 
støtte til? I så fald hvilke? 
• Er der forskel på, om du fik 
den støtte, du havde behov 
for afhængig af om, det var 
læge eller sygeplejersken du 
talte med? 
• Er der problemstillinger, der 
var nemmere / svære at 
drøfte igennem en telefon? 
Indvirkning på dagligdagen • Kan du sætte nogle ord 
på, hvad deltagelsen har 
betydet for din hverdag? 
 
• Hvilken betydning har 
det haft for dig, at du 
ikke skulle møde op 
fysisk i ambulatoriet? 
• Har det haft en praktisk 
betydning? 
• Har det haft en 
arbejdsmæssig betydning? 
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